PubMed Health⌕ Search

PubMed · 16538280

Estimating the number of clusters in DNA microarray data.

Abstract

OBJECTIVES: The main objective of the research is an application of the clustering and cluster validity methods to estimate the number of clusters in cancer tumor datasets. A weighed voting technique is going to be used to improve the prediction of the number of clusters based on different data mining techniques. These tools may be used for the identification of new tumour classes using DNA microarray datasets. This estimation approach may perform a useful tool to support biological and biomedical knowledge discovery. METHODS: Three clustering and two validation algorithms were applied to two cancer tumor datasets. Recent studies confirm that there is no universal pattern recognition and clustering model to predict molecular profiles across different datasets. Thus, it is useful not to rely on one single clustering or validation method, but to apply a variety of approaches. Therefore, combination of these methods may be successfully used for the estimation of the number of clusters. RESULTS: The methods implemented in this research may contribute to the validation of clustering results and the estimation of the number of clusters. The results show that this estimation approach may represent an effective tool to support biomedical knowledge discovery and healthcare applications. CONCLUSION: The methods implemented in this research may be successfully used for the estimation of the number of clusters. The methods implemented in this research may contribute to the validation of clustering results and the estimation of the number of clusters. These tools may be used for the identification of new tumour classes using gene expression profiles.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Nadia Bolshakova, F Azuaje. 2006. Estimating the number of clusters in DNA microarray data.. https://pubmed.ncbi.nlm.nih.gov/16538280/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Progressive vacuolar myelopathy and leukoencephalopathy in childhood acute lymphoblastic leukemia and transient improvement with vitamin B12.

Vacuolar myelopathy (VM) in leukemia is rare. We report a boy with leukemia who developed isolated central nervous system (CNS) relapse during reinduction therapy. 5 months after cranial radiotherapy, he gradually developed quadriparesis. Magnetic resonance imaging revealed an intramedullary lesion which extended through the cervical spine. Serum vitamin B12, folic acid, cerebrospinal fluid methyl malonic acid were normal. Viral screening by ELISA was negative. He had lymphopenia, and reduced immunoglobulins, from a cardiac arrest. Biopsy revealed VM. He responded to weekly vitamin B12 treatment but on the 6th week of the therapy he died after developing periventricular, gliotic, hyperintense lesions in the brain.

Central Nervous System Neoplasms↗

[Extranodal diffuse large B-cell lymphoma--an organotypic disease?].

Roughly 30-40% of diffuse large B-cell lymphomas (DLBCL) arise primarily in extranodal sites. Most frequently, they occur in the gastrointestinal tract, especially in the gastric mucosa. They also occur in the central nervous system, as testicular lymphomas, in the lungs, or in the skin. Morphologically, they show the whole spectrum of peripheral B-blasts: centroblasts, immunoblasts, or plasmoblasts. Thus, there is no actual difference in their cytomorphological presentation compared to their nodal-and frequently systemic-counterparts. However, recent data point to profound differences in primary extranodal DLBCL compared to primary nodal tumors, as well as to each other, frequently relating to their molecular characteristics and especially implying organotypic features. These characteristics may relate to a particular organotypic site of origin, or the particular clinico-pathogenetic setting in which the tumors arise. This is exemplified in the description of the DLBCL subtypes as defined by the World Health Organization classification (mediastinal or intravascular B-cell lymphoma; primary effusion lymphoma). On the other hand, primary extranodal DLBCL are frequently characterized by a particular (cyto-)genetic constitution, often related to their site of origin. Finally, some preliminary data on gene expression profiling strongly argue in favor of particular gene signatures for primary extranodal DLBCL, and hence in favor of particular organotypic transformation pathways.

Central Nervous System Neoplasms↗

Primary CNS lymphoma.

Non-Hodgkin's lymphoma invades the brain, the vitreous body and nerves of the eye, the meninges, and the nerve roots of brain and spine, leading to the development of a primary CNS lymphoma. The mechanism of involvement of these locations by malignant B lymphocytes is unknown, but it might involve molecular targeting of lymphoma cells generated at cryptic systemic sites. The diagnosis of primary CNS lymphoma has been facilitated by advances in imaging techniques and the discovery of molecular markers. Methotrexate-based regimens, even when radiation is deferred, prolong overall survival to over 5 years, but relapses eventually occur in most cases. Better tools for earlier diagnosis and monitoring of treatment response will emerge from molecular studies of therapeutic targets.

Central Nervous System Neoplasms↗